Theravance Inc. (THRX) announced after the bell Thursday that it received a letter from the FDA, which indicated that the company's response to the November 2009 Complete Response letter for the telavancin New Drug Application is incomplete and that the review clock will not start until the FDA receives a complete response.Theravance Inc. gapped down Friday and fell during the first 45 minutes of trade. The stock declined further in the final 90 minutes of the afternoon and closed down by $2.53 at $10.97 on above average volume. Theravance dropped below a 2-month range and set a new low for the year.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.